MedTrace Logo

Asphyxia Associated Metabolite Biomarker Investigation 2

NCT04714502 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 144

Last updated 2021-01-19

No results posted yet for this study

Summary

Follow-up of participants of AAMBI1 study at age of at least 2 years. AAMBI1(ClinicalTrials.gov ID: NCT03354208): Verification of biomarkers in a human population for their ability to diagnose the severity of neonatal asphyxia. These biomarkers linked to asphyxia have been identified in animal studies.

Conditions

  • Birth Asphyxia

Sponsors & Collaborators

  • Cukurova University

    collaborator OTHER

  • University Children's Hospital Tuebingen

    collaborator OTHER

  • InfanDx AG

    lead INDUSTRY

Principal Investigators

  • Ron Meyer · InfanDx AG

Eligibility

Min Age
22 Months
Max Age
48 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-02
Primary Completion
2020-10-31
Completion
2021-12-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04714502 on ClinicalTrials.gov